In spite of the success of PD-1 blockade to enhance overall survival (OS) in multiple tumor types compared to chemo- or radiation therapy, primary resistance to immune checkpoint inhibitors can occur and counteract the actual clinical benefits. Here, PDCD1 is linked to neoplasm.